1-5 of 5
William Wierda, M.D.
Close
Sort by
Journal Articles

Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Adapted Augmented Berlin-Frankfurt-Munster (ABFM) Therapy

Michael Rytting, M.D., Deborah Thomas, M.D., Anna Franklin, M.D., William Wierda, M.D., Stefan Faderl, M.D., Farhad Ravandi, M.D., Brenda Muriera, RN, Hagop M. Kantarjian, MD, Susan O’Brien, M.D.
Journal: Blood
Blood (2008) 112 (11): 3957.
https://doi.org/10.1182/blood.V112.11.3957.3957
Published: 2008
Journal Articles

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Michael Rytting, MD, Deborah Thomas, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Gautam Borthakur, M.D., William Wierda, M.D., Cesar Nunez, M.D., Steven Kornblau, M.D., Farhad Ravandi, M.D., Robert Wells, M.D., Muriera Brenda, R.N., Franklin Anna, M.D., Susan O’Brien, M.D.
Journal: Blood
Blood (2007) 110 (11): 4342.
https://doi.org/10.1182/blood.V110.11.4342.4342
Published: 2007
Journal Articles

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Analysis of 2083 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, M.D., Peter McLaughlin, M.D., Sijin Wen, M.S., William Wierda, M.D., Ph.D., Hagop M. Kantarjian, M.D., John Manning, M.D., Susan Lerner, M.S., Mark Hess, B.B.A., Emil J. Freireich, M.D., Michael J. Keating, M.D.
Journal: Blood
Blood (2006) 108 (11): 2790.
https://doi.org/10.1182/blood.V108.11.2790.2790
Published: 2006
Journal Articles

Imatinib Mesylate for Patients (pts) with Hypereosinophilic Syndrome (HES) and Systemic Mastocytosis (SM): A Phase II Trial.

Elias Jabbour, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Farhad Ravandi-Kashani, M.D., William Wierda, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Jorge Cortes, M.D.
Journal: Blood
Blood (2004) 104 (11): 4752.
https://doi.org/10.1182/blood.V104.11.4752.4752
Published: 2004
Journal Articles

Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashami, M.D., Francis Giles, M.D., Stefan Faderl, M.D., William Wierda, M.D., Jianqin Shan, Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1006.
https://doi.org/10.1182/blood.V104.11.1006.1006
Published: 2004